WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically ...

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical ...

Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...

DYNE-101 improved myotonia by 3.3 seconds at 6 months; gains sustained through 12 months across multiple measures. Accelerated approval filing shifted to late 2026; Phase 3 trial expected to start ...

The last time I wrote about Dyne Therapeutics (NASDAQ:DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article ...

Dyne Therapeutics, a clinical-stage company focused on therapeutics for genetically driven neuromuscular diseases, announced that it will present new clinical data from its Phase 1/2 ACHIEVE trial ...

Dyne Therapeutics, Inc. announced that it will present findings from its DELIVER and ACHIEVE clinical trials at the upcoming 2025 Muscular Dystrophy Association Clinical & Scientific Conference in ...

After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...

Dyne Therapeutics’ experimental treatment for Duchenne muscular dystrophy (DMD) showed promise in new data from a small Phase 1/2 trial dubbed DELIVER, the pharma announced this week. The drug, ...

Joshua Brumm is stepping down as CEO of Dyne Therapeutics Inc. after about five years in the corner office. PureTech looks to return $100M to shareholders after ...

Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...

Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders. It has seven programs in its pipeline, but only two are in clinical trials. Dyne focuses on treating ...